Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Golidocitinib Combined With GemOx in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT07279584 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07279584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07279584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Golidocitinib Combined With GemOx in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 20, 2025
Completion date
December 31, 2027
Enrollment
31 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphomas (ptcl)